Ocera Therapeutics Inc

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Ocera Therapeutics, Inc.

NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky announces it has commenced an investigation of Ocera Therapeutics, Inc. (NASDAQ: OCRX) concerning possible violations of federal securities laws.

On January 30, 2017, Ocera reported the results of its Phase 2b study of Ornithine Phenylacetate were not statistically significant in terms of the primary and secondary endpoints. Upon this news, shares of Ocera fell from a close of $2.05 on January 27, 2017, to a close of $0.60 on January 30, 2017. To obtain additional information, go to:

http://zlk.9nl.com/ocera-ocrx

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
02/02/2017

Underlying

Ocera Therapeutics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ocera Therapeutics Inc

 PRESS RELEASE
Free
Ocera Therapeut...

OCERA THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Ann...

WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.: Do you own shares of Ocera Therapeutics, Inc. (NASDAQ CM: OCRX)? Did you purchase any of your shares prior to November 2, 2017? Do you think the proposed buyout is fair? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Ocera Therapeutics, Inc. (“Ocera” or the “Company”) (NASDAQ CM: OCRX) ...

November 2, 2017 1 EN
 PRESS RELEASE
Free
Ocera Therapeut...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Inve...

NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Ocera Therapeutics, Inc. (“Ocera Therapeutics” or the “Company”) (NASDAQ: OCRX) stock prior to November 2, 2017. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Ocera Therapeutics to Mallinckrodt plc (NYSE: MNK). Under the terms of the transaction, shareholders of Ocera Therapeutics will receive $1.52 per share...

November 2, 2017 1 EN
 PRESS RELEASE
Free
Ocera Therapeut...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of...

NEW YORK--(BUSINESS WIRE)-- Levi & Korsinsky announces it has commenced an investigation of Ocera Therapeutics, Inc. (NASDAQ: OCRX) concerning possible violations of federal securities laws. On January 30, 2017, Ocera reported the results of its Phase 2b study of Ornithine Phenylacetate were not statistically significant in terms of the primary and secondary endpoints. Upon this news, shares of Ocera fell from a close of $2.05 on January 27, 2017, to a close of $0.60 on January 30, 2017. To obtain additional information, go t...

February 2, 2017 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch